IBI306 + placebo + placebo + IBI306
Phase 3Recruiting 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia
Conditions
Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia
Trial Timeline
Apr 1, 2026 → Feb 28, 2027
NCT ID
NCT07473960About IBI306 + placebo + placebo + IBI306
IBI306 + placebo + placebo + IBI306 is a phase 3 stage product being developed by Innovent Biologics for Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07473960. Target conditions include Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07473960 | Phase 3 | Recruiting |
Competing Products
1 competing product in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SHR-1209 ;placebo + SHR-1209 ;placebo + SHR-1209 ;placebo | Jiangsu Hengrui Medicine | Phase 3 | 77 |